Pols, Thijs W.Auwerx, JohanSchoonjans, Kristina2010-07-092010-07-092010-07-09201010.1016/j.gcb.2010.03.009https://infoscience.epfl.ch/handle/20.500.14299/51564WOS:000279493500011Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.Glucagon-Like Peptide-1Incretin-Based TherapiesBile-AcidsTgr5 AgonistL CellsReceptorGlucoseSecretionDerivativesActivationtext::journal::journal article::review article